Update on the treatment of cutaneous T-cell lymphoma (CTCL): Focus on vorinostat

Biologics: Targets and Therapy

Volumn 1, Issue 4, 2007, Pages 377-392

  Duvic, Madeleine ^a   Vu, Jenny ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cutaneous T cell lymphoma (CTCL); Histone deacetylase inhibitors (HDAC inhibitors); Mycosis fungoides (MF); S zary syndrome (SS); Suberoylanilide hydroxamic acid (SAHA); Vorinostat; ZolinzaTM,

Indexed keywords

EID: 77952140455     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: None     Document Type: Article

References (87)

1. Almenara J, Rosato R, Grant S. 2002. Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA). Leukemia, 16:1331-43.
2. Apisarnthanarax N, Talpur R, Ward S, et al. 2004. Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open-label pilot study. J Am Acad Dermatol, 50:600-7.
3. Assaf C, Bagot M, Drummer R, et al. 2006. Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion. Br J Dermatol, 155:261-6.
4. Axelrod P I, Lorber B, Vonderheid EC, et al. 1992. Infections complicating mycosis fungoides and Sezary syndrome. JAMA, 267:1354-8.
5. Berger CL, Hanlon D, Kanada D, et al. 2002. The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells. Blood, 99:2929-39.
6. Blander G, Guarente L. 2004. The Sir2 family of protein deacetylases. Annu Rev Biochem, 73:417-35.
7. Bolden JE, Peart MJ, Johnstone RW. 2006. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov, 5:769-84.
8. Breneman D, Duvic M, Kuzel T, et al. 2002. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. Arch Dermatol, 138:325-32.
9. Butler LM, Agus DB, Marks PA, et al. 2000. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res, 60:5165-70.
10. Butler LM, Agus DB, Scher HI, et al. 2000. Suberoylanilide hydoxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res, 60:5165-70.
11. Butler LM, Liapis V, Bouralexis S, et al. 2006. The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL. Int J Cancer, 119:944-54.
12. Butler LM, Zhou X, Xu WS, et al. 2002. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci USA, 99:11700-5.
13. Cohen LA, Amin S, Marks PA, et al. 1999. Chemoprevention of carcinogeninduced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA). Anticancer Res, 19:4999-5005.
14. Cohen LA, Marks PA, Rifkind RA, et al. 2002. Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors. Anticancer Res, 22:1497-504.
15. de Ruijter AJ, van Gennip AH, Caron HN, et al. 2003. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J, 370:737-49.
16. Deeths MJ, Chapman JT, Dellavalle RP, et al. 2005. Treatment of patch and plaque stage mycosis fungoides with imiquimod 5% cream. J Am Acad Dermatol, 52:275-80.
17. Desai D, Das A, Cohen L, et al. 2003. Chemopreventive efficacy of suberoylanilide hydroxamic acid (SAHA) against 4-(methylnitrosamino)-1(3-pyridyl)-1-butanone (NNK)-induced lung tumorigenesis in female A/J mice. Anticancer Res, 23(1A):499-503.
18. Diwan AH, Prieto VG, Herling M, et al. 2005. Primary Sezary syndrome commonly shows low grade cytologic appearance and absence of epidermotropism. Am J Clin Pathology, 123:510-15.
19. Duvic M, Martin AG, Kim Y, et al. 2001. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol, 137:581-93.
20. Duvic M, Zhang C. 2006. Clinical and laboratory experience of vorinostat (suberoylanilide hydroxamic acid) in the treatment of cutaneous T-cell lymphoma. Br J Cancer, 95 Suppl 1:S13-19.
21. Duvic M, Talpur R, Ni X, et al. 2007. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood, 109:31-9.
22. Foss F, Demierre MF, Divenuti G, et al. 2005. A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood, 106:454-7.
23. Furumai R, Matsuyama A, Kobashi N, et al. 2002. FK228 (Depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res, 62:4916-21.
24. Garcia-Manero G, Yang H, Sanchez-Gonzalez B, et al. 2005. Final results of a phase I study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with leukemia and myelodysplastic syndrome [abstract]. Blood, 106:785a.
25. Giardi M, Heald PW, Wilson LD. 2004. The pathogenesis of mycosis fungoides. N Engl J Med, 350:1978-88.
26. Gore SD, Carducci MA. 2000. Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors. Exp Opin Invest Drugs, 9:2923-34.
27. Gregoretti IV, Lee YM, Goodson HV. 2004. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol, 338:17-31.
28. Gui CY, Ngo L, Xu WS, et al. 2004. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoterassociated proteins, including HDAC1. Proc Natl Acad Sci USA, 101:1241-6.
29. Guo F, Sigua C, Tao J, et al. 2004. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Res, 64:2580-9.
30. He LZ, Tolentino T, Grayson P, et al. 2001. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest, 108:1321-30.
31. Heider U, Kaiser M, Sterz J, et al. 2006. Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma. Eur J Haematol, 76:42-50.
32. Jackow CM, Cather JC, Hearne V, et al. 1997. Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor V beta gene expansion. Blood, 89:32-40.
33. Jackow CM, McHam JB, Friss A, et al. 1996. HLA-DR5 and DQB1*03 class II alleles are associated with cutaneous T-cell lymphoma. J Invest Dermatol, 107:373-6.
34. Kazakov DV, Burg G, Kempf W. 2004. Clinicopathological spectrum of mycosis fungoides. J Eur Acad Dermatol Venereol, 18:397-415.
35. Kelly WK, Marks PA. 2005. Drug insight: Histone deacetylase inhibitorsdevelopment of the new targeted anticancer agent suberoylanilide development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Paract Oncol, 2:150-7.
36. Kelly WK, O'Connor OA, Krug LM, et al. 2005. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol, 23:3923-31.
37. Kelly WK, Richon VM, O'Connor O, et al. 2003. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res, 9(10 Pt 1): 3578-88.
38. Kim EJ, Hess S, Richardson SK, et al. 2005. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest, 115:798-812.
39. Kraken WA, Ward SR, Duvic M. 2003. Bexarotene is a new treatment option for lymphomatoid papulosis. Dermatology, 206:142-7.
40. Lain T, Talpur R, Duvic M. 2003. Long-term control of mycosis fungoides of the hands with topical bexarotene. Int J Dermatol, 42:238-41.
41. Lakshmikanthan V, Kaddour-Djebbar I, Lewis RW, et al. 2006. SAHAsensitized prostate cancer cells to TNFalpha-related apoptosis-inducing ligand(TRAIL): mechanisms leading to synergistic apoptosis. Int J Cancer, 119:221-8.
42. Ledent V, Vervoort M. 2006. Comparative genomics of class 4 histone deacetylases indicates a complex evolutionary history. BMC Biol, 4:24.
43. Lim HW, Edelson RL. 1995. Photopheresis for the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am, 9:1117-26.
44. Lindemann RK, Gabrielli B, Johnstone RW. 2004. Histone-deacetylase inhibitors for the treatment of cancer. Cell Cycle, 3:779-88.
45. Marchion DC, Bicaku E, Daud AI, et al. 2004. Sequence-specific potentiation oftopoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilidehydroxamic acid. J Cell Biochem, 92:223-37.
46. Marchion DO, Bicaku E, Daud AI. 2004. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamine acid. J Cell Biochem, 92:223-37.
47. Marks P, Rifkind RA, Richon VM, et al. 2001. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer, 1:194-202.
48. Marks PA, Breslow R. 2007. Dimethyl sulfoxide to vorinostat: Development of this histone deacetylase inhibitor as an anti-cancer drug. Nature Biotechnology, 25:84-90.
49. Marks PA, Dokmanovic M. 2005. Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin Investig Drugs, 14:1497-511.
50. Marks PA, Jiang X. 2005. Histone deacetylase inhibitors in programmed cell death and cancer therapy. Cell Cycle, 4:549-51.
51. McGinnis KS, Ubriani R, Newton S, et al. 2005. The addition of interferon gamma to oral bexarotene therapy with photopheresis for Sézary syndrome. Arch Dermatol, 141:1176-8.
52. Mei S, Ho AD, Mahlknecht U. 2004. Role of histone deacetylase inhibitors in the treatment of cancer (Review) Int J Oncol, 25:1509.
53. Miller AB, Hoogstraten B, Staquet M, et al. 1981. Reporting results of cancer treatment. Cancer, 47:207-14.
54. Moradei O, Maroun CR, Paquin I, et al. 2005. Histone deacetylase inhibitors: latest developments, trends, and prospects. Curr Med Chem Anticancer Agents, 5:529-60.
55. Ni X, Zhang C, Talpur R, et al. 2005. Resistance to activation-induced cell death and bystander cytotoxicity via the Fas/Fas ligand pathway are implicated in the pathogenesis of cutaneous T cell lymphomas. J Invest Dermatol, 124:741-50.
56. Nimmanapalli R, Fuino L, Stobaugh C, et al. 2003. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood, 101:3236-9.
57. Ocker M, Alajati A, Ganslmayer M, et al. 2005. The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells. J Cancer Res Clin Oncol, 131:385-94.
58. O'Connor OA, Heaney ML, Schwartz L, et al. 2006. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol, 24:166-73.
59. O'Connor OA. 2005. Developing new drugs for the treatment of lymphoma. Eur J Haematol, Suppl(66):150-8.
60. Olsen E, Duvic M, Frankel A, et al. 2001. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol, 19:376-88.
61. Olsen E, Kim YH, Kuzel T, et al. 2007. Phase IIB. Multicenter trial of Vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol, Jun 18 Epub. Picardo DA,
62. Querfeld C, Guitart J, et al. 2004. Cutaneous T-cell lymphoma: a paradigm for biological therapies. Leukemia and Lymphoma, 45:1755-65.
63. Piekarz R, Bates S. 2004. A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. Curr Pharm Des, 10:2289-98.
64. Piekarz RL, Robey R, Sandor V, et al. 2001. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood, 98:2865-8.
65. Piekarz RL, Robey RW, Zhan Z, et al. 2004. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood, 103:4636-43.
66. Piekarz RL, Robey RW, Zhan Z, et al. 2004. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide onmolecular markers, therapeutic targets, and mechanisms of resistance. Blood, 103:4636-43.
67. Prince HM, George DJ, Johnstone R, et al. 2006. LBH589 a novel deacetylase inhibitor (DACi), treatment of patients with cutaneous T-cell lymphoma (CTCL): skin gene expression profiles in the first 24 hours related to clinical response following therapy. Presented at 2006 ASH Annual Meeting, Orlando, FL.
68. Querfeld C, Rosen ST, Guitart J, et al. 2005. The spectrum of cutaneous T-cell lymphomas: new insights into biology and therapy. Current Opinion in Hematology, 12:273-8.
69. Reddy P, Maeda Y, Hotary K, et al. 2004. Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc Natl Acad Sci USA, 101:3921-6.
70. Richon VM, Emiliani S, Verdin E, et al. 1998. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA, 95:3003-7.
71. Richon VM, Sandhoff TW, Rifkind RA, et al. 2000. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA, 97:10014-19.
72. Rook AH, Gottlieb SL, Wolfe JT, et al. 1997. Pathogenesis of cutaneous T-cell lymphoma: implications for the use of recombinant cytokines and photopheresis. Clin Exp Immunol, 107(Suppl 1):16-20.
73. Rosato RR, Almenara JA, Dai Y, et al. 2003. Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosisinducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol Cancer Ther, 2:1273-84.
74. Sakajiri S, Kumagai T, Kawamata N, et al. 2005. Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Exp Hematol, 33:53-61.
75. Sandor V, Senderowicz A, Mertins S, et al. 2000. P21-dependent G1 arrest withdownregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylaseinhibitor FR901228. British Journal of Cancer, 83:817-25.
76. Shao Y, Gao Z, Marks PA, et al. 2004. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA, 101:18030-5.
77. Shimakage M, Sasagawa T, Kawahara K, et al. 2001. Expression of EpsteinBarr virus in cutaneous T-cell lymphoma including mycosis fungoides. Int J Cancer, 92:226-31.
78. Somech R, Izraeli S, Simon J. 2004. Histone deacetylase inhibitors a new tool to treat cancer. Cancer Treat Rev, 30:461-72.
79. Sommer VH, Clemmensen OJ, Nielsen O, et al. 2004. In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3. Leukemia, 18:1288-95.
80. Steele N, Vidal L. 2005. A phase 1 pharmacokinetic (PK) andpharmacodynamic (PD) study of the histone deacetylase (HDAC) inhibitor PXD101in patients (pts) with advanced solid tumours. J Clin Oncol, 23(16 Suppl):3035.
81. Tan RS, Butterworth CM, McLaughlin H, et al. 1974. Mycosis fungoides-a disease of antigen persistence. Br J Dermatol, 91:607-16.
82. Tokura Y, Yagi H, Ohshima A, et al. 1995. Cutaneous colonization with staphylococci influences the disease activity of Sezary syndrome: a potential role for bacterial superantigens. Br J Dermatol, 133:6-12.
83. Turkson J. 2004. STAT proteins as novel targets for cancer drug discovery. Expert Opin Ther Targets, 8:409-22.
84. Ungerstedt JS, Sowa Y, Xu WS, et al. 2005. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA, 102:673-8.
85. Vega F, Luthra R, Medeiros LJ, et al. 2002. Clonal heterogeneity in mycosis fungoides and its relationship to clinical course. Blood, 100:3369-73.
86. Vrana JA, Decker RH, Johnson CR, et al. 1999. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/ Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene, 18:7016-25.
87. Zhang C, Richon V, Ni X, et al. 2005. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol, 125:1045-52